EyePoint Pharmaceuticals, Inc.

For the quarter ended March 31, 2026, total net revenue was $0.7 million versus $24.5 million in the prior-year quarter. Operating expenses were $88 million versus $73 million a year ago, net non-operating income was $2 million, and net loss was $85 million, or $0.99 per share, compared with a net loss of $45 million, or $0.65 per share, in the prior-year period. Cash, cash equivalents and investments in marketable securities were $223 million at March 31, 2026, down from $306 million at December 31, 2025. Management said that cash is expected to fund operations into the fourth quarter of 2027, beyond key Phase III wet AMD milestones expected later this year.

Jay Duker framed the quarter as steady execution ahead of a pivotal period for DURAVYU. He emphasized that the company remains on track for wet AMD top-line data starting mid-year, while DME enrollment is moving quickly toward third-quarter 2026 completion. His tone was confident and strategic, repeatedly pointing to DURAVYU’s differentiated multi-mechanism profile, durability, and commercial potential in the two largest retinal disease markets.

George Elston focused on liquidity, spending, and the quarter’s financial bridge. He said EyePoint ended the quarter with $223 million in cash and investments, and that this should fund operations into the fourth quarter of 2027. Revenue fell to $0.7 million from $24.5 million, which he attributed mainly to remaining deferred revenue from the 2023 YUTIQ rights deal, while operating expenses rose to $88 million from $73 million due to the ongoing Phase III trials and scale-up of the Northbridge manufacturing facility.

Analysts focused on DME enrollment momentum, supplement/rescue rates in the wet AMD trials, the implications of the fixed-dose redosing regimen, and whether safety could hold up through later doses. Management said investigators are excited about the patient burden reduction potential in DME, that all 90 invited wet AMD investigators accepted DME roles, and that they do not disclose aggregated supplement rates while the data remain masked. On safety, they said they have not seen anything new versus prior trials and expect to provide a formal update after the upcoming DSMB/DMC review in May. On competition, management argued there is room for multiple long-acting TKI products because durability remains the top unmet need in wet AMD.